I have an example just the other day of how reasonable it would be if the company got only 15,000 patients for GBM alone in the markets it is in only currently, and how that could easily generate a substantial price per share with 1.5 billions shares outstanding. If it extends the indications beyond GBM to new and recurrent cancers in various indications, and assuming the Flaskworks scaling works in terms of manufacturing, which I have no reason to not expect, in a few years it certainly could reach a very substantial market cap, engage in share buybacks and reach a substantial per share value.
Plus you can have irrational enthusiasm as we see with Tesla.